KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.

Financial Highlights

  • Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.
  • Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.
  • Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26.

“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%,” said Brian Webster, President and CEO. “We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”

First Quarter Fiscal 2027 Financial Results

  • Total revenue was $31.0 million, an increase of 60% compared to the prior year period.
    • Revenue growth was driven by several factors, including wearable cardioverter defibrillator (WCD) market expansion, competitive share gains, new sales territories, higher mix of in-network patients, and ongoing improvements in revenue cycle management capabilities.
  • Gross profit was $17.5 million compared to $8.9 million in the prior year period.
    • Gross margin expanded to 56.5% compared to 45.7% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.
  • GAAP operating expenses were $55.2 million compared to $37.7 million in the prior year period.
    • Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $44.2 million compared to $30.3 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company’s commercial expansion and accelerated investment in key R&D programs.
  • GAAP net loss was $44.1 million compared to GAAP net loss of $25.8 million in the prior year period.
    • Adjusted EBITDA* loss was $24.0 million compared to an adjusted EBITDA loss of $19.4 million in the prior year period.
  • Cash and cash equivalents, and investments totaled $244.7 million as of July 31, 2026.
    • Including committed unused availability under the company’s term loan agreement, Kestra has total liquidity of approximately $320 million.

*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See “Use of Non-GAAP Financial Measures” below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.

Fiscal Year 2027 Revenue Guidance
Kestra is increasing its FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26. This compares to prior FY27 revenue guidance of $137 million.

Webcast and Conference Call
Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.

About Kestra
Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Use of Non-GAAP Financial Measures
This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including adjusted operating expense and adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.

Adjusted operating expense is calculated as operating expenses, as adjusted to exclude share-based compensation expense and non-recurring expenses. Adjusted EBITDA is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring expenses. Both metrics are presented because management believes they will allow investors to view Kestra’s performance in a manner similar to the method used by management to evaluate Kestra’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of adjusted operating expenses and adjusted EBITDA, in addition to considering Kestra’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.

The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of adjusted operating expenses and adjusted EBITDA reported in this press release to the most comparable respective GAAP measure for the respective periods appears in the tables captioned “Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses” and “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.

Forward-Looking Statements
Except where otherwise noted, the information contained in this press release is as of September 14, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, Kestra undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects, potential growth, and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “continue,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “advance,” “remain,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share amounts)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
Revenue   $ 30,971     $ 19,371  
Cost of revenue     13,473       10,520  
Gross profit     17,498       8,851  
Operating expenses:            
Research and development     6,796       4,001  
Selling, general and administrative     48,359       33,728  
Total operating expenses     55,155       37,729  
Loss from operations     (37,657 )     (28,878 )
Other expense (income):            
Interest expense     1,929       1,912  
Interest income     (2,125 )     (2,167 )
Other expense (income), net     272       (2,830 )
Loss on extinguishment of debt     6,304       —  
Net loss before provision for income taxes     (44,037 )     (25,793 )
Provision for income taxes     50       33  
Net loss attributable to common shareholders, basic and diluted   $ (44,087 )   $ (25,826 )
             
Net loss per share attributable to common shareholders, basic and diluted   $ (0.75 )   $ (0.50 )
Weighted-average common shares outstanding, basic and diluted     58,566,467       51,304,599  
             
Other comprehensive loss:            
Net loss   $ (44,087 )   $ (25,826 )
Unrealized loss on marketable securities     (253 )   —  
Comprehensive loss   $ (44,340 )   $ (25,826 )

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
(unaudited)

    July 31,     April 30,  
    2026     2026  
             
Assets            
Current assets            
Cash and cash equivalents   $ 68,558     $ 99,710  
Short-term investments     130,353     $ 96,724  
Accounts receivable, net     15,406       14,542  
Disposable medical equipment supplies     7,438       6,706  
Prepaid expenses and other current assets     4,518       4,677  
Total current assets     226,273       222,359  
             
Long-term investments     45,791       65,767  
Right-of-use assets     3,263       3,364  
Deposits     1,842       1,761  
Restricted cash     334       334  
Property and equipment, net     63,656       59,090  
Other long-term assets     6,196       5,790  
Total assets   $ 347,355     $ 358,465  
             
Liabilities and Shareholders’ Equity            
Current liabilities            
Accounts payable   $ 25,961     $ 27,295  
Accrued liabilities     22,285       23,046  
Operating lease liabilities, current portion     23       31  
Total current liabilities     48,269       50,372  
             
Operating lease liabilities, net of current portion     3,928       4,111  
Warrant liabilities   —       1,369  
Other long-term liabilities     306       306  
Long-term debt, net     72,495       42,649  
Total liabilities     124,998       98,807  
             
Commitments and contingencies            
             
Shareholders’ equity            
             
Common Shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2026 and April 30, 2026; 59,271,885 issued and outstanding as of July 31, 2026 and 58,383,924 shares issued and outstanding as of April 30, 2026     59,272       58,384  
Additional paid-in capital     859,504       853,353  
Accumulated other comprehensive loss     (471 )     (218 )
Accumulated deficit     (695,948 )     (651,861 )
Total shareholders’ equity     222,357       259,658  
Total liabilities and shareholders’ equity   $ 347,355     $ 358,465  

KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
Cash flows from operating activities            
Net loss   $ (44,087 )   $ (25,826 )
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation and amortization     2,664       2,028  
Loss on disposal of property and equipment     292       280  
Reserve for equipment and supplies     1,464       412  
(Recovery) provision for uncollectible accounts receivable     (817 )     613  
Amortization (accretion) of premiums (discounts) on securities, net     (890 )   —  
Loss on extinguishment of debt     6,304     —  
Amortization of debt discounts and issuance costs     408       469  
Share-based compensation expense     9,517       4,579  
Non-cash lease expense     103       61  
Change in fair value of warrant liabilities     251       (2,909 )
Changes in operating assets and liabilities:            
Disposable medical equipment supplies     (908 )     (460 )
Prepaid expenses and other current assets     246       140  
Accounts receivable     (48 )     (1,777 )
Accounts payable     (1,879 )     (2,896 )
Accrued liabilities     (4,727 )     (860 )
Operating lease liabilities     (190 )     (138 )
Other long-term assets     2       10  
Net cash used in operating activities     (32,295 )     (26,274 )
Cash flows from investing activities            
Purchases of property and equipment     (8,335 )     (8,166 )
Deposits for medical rental equipment   —       (103 )
Refund of deposits for medical rental equipment   —       37  
Purchase of marketable securities     (13,017 )     —  
Net cash used in investing activities     (21,352 )     (8,232 )
Cash flows from financing activities            
Proceeds from issuance of long-term debt     75,000     —  
Payment of debt issuance costs     (3,193 )   —  
Repayment of long-term debt     (46,395 )   —  
Payment of early termination fee on debt repayment     (3,758 )      
Payment of IPO offering costs     —       (1,875 )
Payment of equity issuance costs     (415 )   —  
Deemed dividend for payments to third party on behalf of shareholder     (172 )   —  
Proceeds from stock option exercises     1,140     —  
Proceeds from Employee Stock Purchase Plan     1,298     —  
Tax withholdings on restricted stock unit vesting     (1,010 )   —  
Net cash provided by (used in) financing activities     22,495       (1,875 )
Net decrease in cash, cash equivalents and restricted cash     (31,152 )     (36,381 )
Cash, cash equivalents and restricted cash            
Beginning of period     100,044       237,929  
End of period   $ 68,892     $ 201,548  

RECONCILIATION OF CASH AND CASH EQUIVALENTS TO CASH, CASH EQUIVALENTS, AND INVESTMENTS
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
Cash and cash equivalents   $ 68,558     $ 201,214  
Add: Short-term investments     130,353     —  
Add: Long-term investments     45,791     —  
Cash, cash equivalents, and investments   $ 244,702     $ 201,214  

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
GAAP Net loss   $ (44,087 )   $ (25,826 )
Non-GAAP Adjustments:            
Interest expense     1,929       1,912  
Interest income     (2,125 )     (2,167 )
Other expense (income)     272       (2,830 )
Provision for income taxes     50       33  
Depreciation expense     2,664       2,028  
Share-based compensation expense     9,517       4,579  
Loss on extinguishment of debt     6,304       —  
Non-recurring expenses     1,430       2,866  
Adjusted EBITDA   $ (24,046 )   $ (19,405 )

RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES
(in thousands)
(unaudited)

    Three Months Ended July 31,  
    2026     2025  
             
GAAP Operating Expenses   $ 55,155     $ 37,729  
Non-GAAP Adjustments:            
Share-based compensation expense     9,517       4,579  
Non-recurring expenses     1,430       2,866  
Adjusted Operating Expenses   $ 44,208     $ 30,284  
CONTACT: Investor Relations
Neil Bhalodkar
neil.bhalodkar@kestramedical.com

Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules

LOUISVILLE, Colo., Sept. 14, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that Brianna Phillips, Vice President of Quality and Regulatory Affairs at Biodesix, will be presenting at the upcoming Regulatory Affairs Professionals Society (RAPS) and Society of Clinical Research Associates (SOCRA) Annual Meetings.

These important professional society meetings put a spotlight on the material influence and need for Quality Affairs and Regulatory Affairs (QA/RA) expertise in the medical diagnostics segment. Under Brianna’s leadership, Biodesix QA/RA is a strategic, differentiating advantage for the company’s five on-market diagnostic blood tests. Excellence in QA/RA has helped propel Biodesix in transforming the healthcare pathway for patients with indeterminate lung nodules.

For the past 12 years, while leading the QA/RA team at Biodesix, Brianna has established the full portfolio of QA/RA accreditations for two Biodesix Labs: CLIA, CAP, NYS CLEP, ISO 13485, and FDA. She also led the company’s efforts in establishing a Good Manufacturing Practices (GMP) FDA-registered facility. Her team has completed countless successful audits by domestic auditing bodies as well as international pharmaceutical partners’ auditors.

These Lab certifications, the track record of successful audits and improvements to processes, and the high bar for excellence in quality standards are a remarkable achievement in that of the tens of thousands of labs nationally, there are only ~1,135 NYS CLEP labs and only ~7,000 CAP-accredited labs, cementing Biodesix Labs into a rare class of diagnostics peers.

At their root, the Biodesix Quality Management System and Regulatory Compliance processes are critical to accelerate patient care excellence as well as patient access to the Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Risk Assessment testing portfolios. These tests have already impacted the lives of more than 100,000 patients in a few short years.

With her unique breadth and depth in QA/RA across multiple medical industry segments, Brianna will be sharing her expertise at these September events:

Regulatory Affairs Professionals Society (RAPS), Annual Convergence Event, Charlotte NC:

Society of Clinical Research Associates (SOCRA) Annual Meeting, Denver, CO: 

Brianna’s impact goes far beyond Biodesix and the healthcare providers and patients that benefit from the company’s blood tests today. Additionally, she offers her leadership to the next generation of QA/RA professionals as a member of the QA/RA Advisory Board for the Biomedical Engineering Department at the University of Colorado Denver | Anschutz, as Guest Professor for the Quality Certificate Program at CU Anschutz, and as Chair-Elect of the Colorado Chapter of RAPS.

About Biodesix:

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com and KnowYourNodule.com.

Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
natalie.stdenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843

Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)

CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the Company will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial (NCT06847191) evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is believed to reduce inflammation and improve insulin sensitivity, in Long COVID.

Michael Peluso, MD, MHS, Associate Professor of Medicine, University of California, San Francisco, and an investigator in the trial, and Ezra Spier, Long COVID patient advocate and a patient advisor on the ADDRESS-LC trial, will be guest speakers at the event. A live Q&A session with management will follow the presentation.

Registration Details

Date:                   September 15, 2026
Time:                   8:30am ET
Registration:        Click here

A replay will be available on the BioVie website following the event.

About the ADDRESS-LC trial

The Phase 2 ADDRESS-LC study (NCT06847191), which is fully funded by a grant from the U.S. Department of War (DoW), is a randomized (1:1), placebo-controlled, signal-finding proof-of-concept, multicenter trial evaluating the efficacy, safety and tolerability of bezisterim in adult participants with Long COVID who have cognitive impairment sequelae and fatigue. The study compared bezisterim, administered as a 20 mg oral capsule twice daily, with a matching placebo to assess its effects on neurocognitive and fatigue-related symptoms. The trial evaluated 22 clinical outcome measures, with no single endpoint pre-specified as the primary determinant of study success. Endpoints include assessing changes in overall clinical benefit, subjective and objective cognitive function, fatigue, sleep disturbance, Quality of Life and PEM. As a signal-finding study, the trial was designed to identify efficacy signals, measure treatment effect magnitude, and identify patient subgroups most likely to benefit, to inform the design of future Phase 3 trials.

About Bezisterim

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNFα), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease (PD), Long COVID (LC), and Alzheimer’s disease (AD).

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate).

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.

Terms of the U.S. Department of War (DoW) Award

The work is supported by the Assistant Secretary of War for Health Affairs and endorsed by the DoW by a fully funded award in the amount of $13.13 million through the Peer-Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations in this press release are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the DoW.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” “potential,” “may,” or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson’s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company’s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries:
        
Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com

For Media Inquiries:
        
Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com

SOUTHAMPTON, Pa., Sept. 14, 2026 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTCID: ETCC) (“ETC” or the “Company”) announced that it was awarded three contracts totaling $11.7 million. ETC’s Aircrew Training Systems business unit (“ATS”) was awarded two contracts. The first contract is for the system upgrade of the United States Navy Spatial Disorientation research device. The second contract is for the delivery of a Hypobaric Chamber for an international customer. In addition, ETC Sterilizations Systems Unit has been awarded a contract from a global medical device manufacturer. The contract is for the fabrication and installation of a large-capacity vacuum drying chamber. 

“These contracts represent the continuing strong relationship ETC has with its global aeromedical and sterilizer systems customers,” stated Robert Laurent, Jr., ETC’s Chief Executive Officer and President.

About ETC:
ETC designs, manufactures, and sells software driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC is headquartered in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements
This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

CONTACT: Contact: Tim Kennedy, CFO
Phone: (215) 355-9100 
E-mail: info@etcusa.com

  • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated
  • A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October
  • Additional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking presentation at the Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany taking place on October 27-30, 2026
  • Well-capitalized with cash, as of June 30, 2026, of approximately $180 million.

HAYWARD, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage biotechnology company developing disease-modifying genetic medicines for life-threatening, genetically defined diseases, based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its full fiscal year ended June 30, 2026, and provided an update on recent regulatory interactions and upcoming clinical data presentations.

“This has been an important year of clinical execution for Benitec and for the continued development of BB-301,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “Over the course of the year, we completed the follow-up of all six patients in Cohort 1 and fully enrolled Cohort 2, while continuing the regulatory interactions required to prepare BB-301 for advancement into a pivotal trial. The consistency and durability of the clinical benefit observed to date, together with the discussions we have had with the FDA regarding pivotal study plans, continue to strengthen our conviction in the potential of BB-301 to meaningfully alter the course of OPMD-related dysphagia. We are grateful to the patients, families and investigators who have enabled this progress, and we look forward to building on this momentum as we work toward the planned initiation of the pivotal study in mid-2027.”

Clinical Highlights

The Company continues to advance BB-301 through clinical development in the ongoing Phase 1b/2a Clinical Study evaluating the safety and clinical efficacy of locally-administered BB-301 for the treatment of OPMD-related dysphagia.

Interim Clinical Study Update

  • All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated
  • Clinically meaningful improvements (combined with a favorable safety profile) were observed across patient-reported swallowing symptom evaluations and X-ray based swallowing function evaluations, including improved throat closing ability, throat emptying ability, throat muscle relaxation, and functional swallowing ability
  • Interim clinical results for Cohort 1 and Cohort 2 will be presented at the 33rd Annual Congress of the European Society of Gene & Cell Therapy in Hamburg, Germany, October 27-30, 2026

Regulatory Update

  • A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October

Upcoming Catalysts

  • Presentation of interim clinical results from the Phase 1b/2a study at the ESGCT Annual Congress in Hamburg, Germany, October 27-30, 2026.
  • Benitec anticipates initiating the BB-301 pivotal trial in mid-2027.

Financial Highlights

Full Year 2026 Financial Results

For the year ended June 30, 2026, the Company reported total expenses of $51.2 million compared to $41.8 million for the year ended June 30, 2025. Research and development expenses were $23.4 million in 2026, up from $18.3 million in 2025, and were primarily related to the ongoing clinical development of BB-301 for the treatment of OPMD. The increase in research and development expenses primarily reflected higher share-based compensation of $6.3 million and increased payroll of $2.2 million, partially offset by a reduction in contract manufacturing activity of $3.8 million.

General and administrative expenses totaled $27.8 million in 2026 compared to $23.4 million in 2025. The increase was primarily driven by higher share-based compensation of $2.7 million and an increase in payroll of $0.8 million.

The net loss from operations for the year ended June 30, 2026, was $51.2 million compared to $41.8 million for the prior year. Net loss attributable to shareholders for the year ended June 30, 2026 was $45.5 million, or $0.98 per basic and diluted share, compared to a net loss of $37.9 million, or $1.05 per basic and diluted share, for the year ended June 30, 2025. As of June 30, 2026, the Company had $180.0 million in cash and cash equivalents.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1 (the causative gene for OPMD). The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. BB-301 is administered locally, in a one-time procedure, to the muscles in the throat that drive the swallowing process, an approach designed to maximize local benefit and minimize systemic exposure. We believe the silence and replace mechanism of BB-301 is uniquely positioned for the treatment of OPMD by slowing or halting mutant PABPN1 expression while simultaneously providing a functional replacement protein. BB-301 has received Orphan Drug Designation from the EMA and Orphan Drug and Fast Track Designations from the FDA and is currently being evaluated in a Phase 1b/2a, first-in-human, open-label dose escalation study to evaluate the safety and clinical activity of intramuscular doses of BB-301 administered to subjects with OPMD (NCT06185673).

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company’s proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company’s lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia. For additional information, visit www.benitec.com.

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec’s plans to develop and commercialize its product candidates, the timing of the completion of preclinical and clinical trials, the timing of the availability of data from our clinical trials, the timing and sufficiency of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings and other regulatory steps, and the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: the success of our plans to develop and potentially commercialize our product candidates; the timing of the completion of preclinical studies and clinical trials; the timing and sufficiency of patient enrollment and dosing in any future clinical trials; the timing of the availability of data from our clinical trials; the timing and outcome of regulatory filings and approvals; the development of novel AAV vectors; our potential future out-licenses and collaborations; the plans of licensees of our technology; the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, including the potential duration of treatment effects and the potential for a “one shot” cure; our intellectual property position and the duration of our patent portfolio; expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability to access additional financing given market conditions and other factors; the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business plan; unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; regulatory developments in the United States of America; the Company’s ability to protect and enforce its patents and other intellectual property rights; the Company’s dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace and market competition; reliance on third party manufacturers and suppliers, and the risks associated with manufacturing complexity, supply interruptions, and compliance with current good manufacturing practices, sales, marketing and distribution requirements for our product candidates; greater than expected expenses; including expenses relating to litigation or strategic activities; our incurrence of significant losses and the uncertainty of our ability to achieve or sustain profitability or generate any revenue; the Company’s ability to satisfy its capital needs through increasing revenue and obtaining additional financing; the impact of local, regional, national and international economic conditions and events; including geopolitical instability, and risks associated with conducting business and seeking regulatory approvals in international markets; our ability to attract and retain key management, scientific, and technical personnel; cyber-security threats and vulnerabilities in our and our third parties’ information technology systems; the impact of legislative and regulatory reforms affecting drug pricing and reimbursement, including Medicare drug-price negotiation and government pricing frameworks; potential product liability claims arising from the use of our product candidates in clinical trials or following any future marketing approval; physicians, patients, third-party payers, or others in the medical community may not be receptive to our product candidates, and we may not generate any future revenue from the sale or licensing of our product candidates; and disruptions to U.S. government agency operations, including FDA staffing changes; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Contact:
Audra Friis
Sam Brown Healthcare Communications
(917) 519-9577
audrafriis@sambrown.com

Source: Benitec Biopharma Inc.

BENITEC BIOPHARMA INC.
Consolidated Balance Sheets
(in thousands, except par value and share amounts)
             
    June 30,
2026
    June 30,
2025
 
Assets            
Current assets:            
Cash and cash equivalents   $ 179,972     $ 97,744  
Restricted cash     114       113  
Trade and other receivables     4       33  
Prepaid and other assets     1,595       628  
Total current assets     181,685       98,518  
Property and equipment, net     178       131  
Deposits     55       55  
Prepaid and other assets     12       28  
Right-of-use assets     693       860  
    Total assets   $ 182,623     $ 99,592  
             
Liabilities and Stockholders’ Equity            
Current liabilities:            
Trade and other payables   $ 4,295     $ 1,022  
Accrued employee benefits     553       426  
Lease liabilities, current portion     496       354  
Total current liabilities     5,344       1,802  
Lease liabilities, less current portion     266       495  
    Total liabilities     5,610       2,297  
             
Stockholders’ equity:            
Preferred stock, $0.0001 par value—5,000,000 shares authorized; no shares
issued or outstanding at June 30, 2026 and June 30, 2025, respectively
    —       —  
Common stock, $0.0001 par value—160,000,000 shares authorized; 34,416,834 and
26,250,469 shares issued and outstanding at June 30, 2026 and June 30, 2025,
respectively
    3       2  
Additional paid-in capital     451,695       326,308  
Accumulated deficit     (273,722 )     (228,176 )
Accumulated other comprehensive loss     (963 )     (839 )
    Total stockholders’ equity     177,013       97,295  
        Total liabilities and stockholders’ equity   $ 182,623     $ 99,592  
BENITEC BIOPHARMA INC.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
       
    Year Ended  
    June 30,  
    2026     2025  
Operating expenses:            
Research and development     23,388       18,332  
General and administrative     27,804       23,433  
Total operating expenses     51,192       41,765  
Loss from operations     (51,192 )     (41,765 )
Other income (loss):            
Foreign currency transaction gain (loss)     120       (71 )
Interest income, net     5,569       3,286  
Other expense, net     (43 )     (131 )
Gain on extinguishment of liabilities     —       764  
Total other income, net     5,646       3,848  
Net loss   $ (45,546 )   $ (37,917 )
Other comprehensive income:            
Unrealized foreign currency translation gain (loss)     (124 )     53  
Total other comprehensive income (loss)     (124 )     53  
Total comprehensive loss   $ (45,670 )   $ (37,864 )
Net loss   $ (45,546 )   $ (37,917 )
Net loss attributable to common shareholders   $ (45,546 )   $ (37,917 )
Net loss per share:            
Basic and diluted   $ (0.98 )   $ (1.05 )
Weighted average number of shares outstanding:            
Basic and diluted     46,558,162       36,209,271  

PRESS RELEASE 
  
September 14th, 2026

  

RCI BANQUE LAUNCHES A DUAL-TRANCHE BOND ISSUE IN EURO: 750 MILLION MATURING IN 2031 AND 500 MILLION MATURING IN 2033

RCI Banque, operating under its commercial brand Mobilize Financial Services, priced a €1.25 billion dual-tranche bond offering comprising a €750 million February 2031 bond with a 4.625% coupon and a €500 million November 2033 bond with a 5.00% coupon.

The issuance was very well received by investors, with the shorter tranche attracting around €1.6 billion of demand from more than 110 accounts and the longer tranche generating approximately €1.1 billion of orders from over 90 investors.

Contact

Analysts and Investors

Financial communication

+ 33(0) 1 76 88 81 74

contact_investor@rcibanque.com

About Mobilize Financial Services   
Attentive to the needs of all its customers, Mobilize Financial Services, a subsidiary of Renault Group, creates innovative financial services to build sustainable mobility for all. Mobilize Financial Services, which began operations nearly 100 years ago, is the commercial brand of RCI Banque SA, a French bank specializing in automotive financing and services for customers and networks of Renault Group, and also for the brands Nissan and Mitsubishi in several countries.   
With operations in 35 countries and nearly 4,000 employees, Mobilize Financial Services financed more than 1,270,556 contracts (new and used vehicles) at the end of 2025 and sold 3.6 million services. At the end of 2025, average earning assets stood at 59.3 billion euros of financing and pre-tax earnings at 1,181 million euros.    
Since 2012, the Group has deployed a deposit-taking business in several countries. At the end of 2025, net deposits amounted to 29.9 billion euros, or 46.8 % of the company’s net assets.    
To find out more about Mobilize Financial Services: www.mobilize-fs.com/   
Follow us on Twitter: @Mobilize_FS  

Attachment

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) subsidiary, Neutra Life Sciences (“NLS”), has expanded its 2026 industry conference schedule with the addition of three new events — Partnership with Sites, DPharm: Disruptive Innovations to Advance Clinical Trials, and Fall Clinical – Dermatology — as part of its ongoing strategy to deepen sponsor and CRO relationships and expand trial opportunities across its growing site network.

The additions build on NLS’s previously announced attendance at the SCRS Global Site Solutions Summit and Obesity Week 2026, bringing the Company’s confirmed 2026 conference schedule to five events. Neutra Life Sciences will use each engagement to connect directly with sponsors and CROs, showcase its multi-site network, and identify new trial and partnership opportunities for its investigative sites.

“Every conference on this schedule is about the same goal — putting Neutra Life Sciences in front of the sponsors and CROs who can bring new trials into our network,” said Sydney Jim, President and CEO of Neutra Corp. “Adding Partnership with Sites, DPharm, and Fall Clinical – Dermatology gives us more touchpoints with the people who decide where trials go, and we intend to leave each one with new relationships and new opportunities for our sites.”

Industry Conference Presence

As part of its ongoing outreach strategy, Neutra Life Sciences will attend the following industry conferences in 2026:

Partnership with Sites (September 14, 2026) – Partnership with Sites brings together clinical trial site leaders, sponsors, and CROs to explore new collaboration models across the site management landscape. Neutra Life Sciences will attend to connect with sponsors and CROs and highlight its growing multi-site network.

DPharm: Disruptive Innovations to Advance Clinical Trials (September 15–16, 2026) – DPharm convenes pharmaceutical, biotech, and clinical operations leaders to discuss innovative approaches to trial design and execution. Neutra Life Sciences will attend to engage with sponsors and CROs exploring new site partnership models.

Fall Clinical – Dermatology (October 8–11, 2026) – Fall Clinical is a leading dermatology conference bringing together clinicians, researchers, and industry partners. Neutra Life Sciences will attend to strengthen relationships with dermatology sponsors and CROs and showcase its investigative site network in the specialty.

SCRS Global Site Solutions Summit (October 15–18, 2026) – The Society for Clinical Research Sites (SCRS) Global Summit is the premier gathering of clinical research site professionals and industry stakeholders. Neutra Life Sciences will attend to engage with sponsors, CROs, and fellow site operators, showcase its growing multi-site network, and identify new trial and partnership opportunities.

Obesity Week 2026 (November 14–17, 2026) – Obesity Week is the largest international conference dedicated to the science and treatment of obesity, convening leading researchers, clinicians, and industry professionals. Neutra Life Sciences’ attendance underscores its commitment to expanding its therapeutic area footprint and engaging sponsors and CROs active in metabolic and obesity-related clinical research.

Site Update: Women’s Health Care Center of Baytown

Neutra Life Sciences has also successfully started operations at Women’s Health Care Center of Baytown, the clinical research site partnership the Company announced in June 2026. The site is now successfully enrolling patients in two indications — early pregnancy and breast cancer screening — adding to NLS’s growing base of active investigative sites.

For more information about partnering with Neutra Life Sciences, please contact:

info@neutralifesciences.com

www.neutralifesciences.com

About Neutra Corp

Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.

Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.

Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com

About Neutra Life Sciences

Neutra Life Sciences is a clinical research site management organization that is comprised of multiple clinical research sites across various specialties. Their network of Principal Investigators are passionate about advancing medical research and improving healthcare outcomes.

Neutra Life Sciences is dedicated to transforming clinical research through a patient-centric approach. They specialize in optimizing trial operations, enhancing patient experiences, and delivering high-quality data to advance medical innovation.

Their mission is to bridge the gap between cutting-edge clinical trials and the communities that need them most. By fostering strong partnerships with investigators, sponsors, and CROs, we ensure efficient study execution while prioritizing patient safety, comfort, and engagement.

With a team of experienced research professionals, Neutra Life Sciences seamlessly integrates proprietary Standard Operating Procedures (SOPs) with industry best practices to ensure efficiency, compliance, and the highest standards of patient care in every clinical trial we manage. They have an unwavering commitment to excellence, integrity, and innovation drives us to make a meaningful impact in clinical research—one patient at a time.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts
Neutra Corp.
Sydney Jim, 307-228-1488
President and CEO
info@neutrainc.com

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced that its wholly owned clinical research Site Management Organization (SMO) subsidiary, Neutra Life Sciences (“NLS”), has expanded its 2026 industry conference schedule with the addition of three new events — Partnership with Sites, DPharm: Disruptive Innovations to Advance Clinical Trials, and Fall Clinical – Dermatology — as part of its ongoing strategy to deepen sponsor and CRO relationships and expand trial opportunities across its growing site network.

The additions build on NLS’s previously announced attendance at the SCRS Global Site Solutions Summit and Obesity Week 2026, bringing the Company’s confirmed 2026 conference schedule to five events. Neutra Life Sciences will use each engagement to connect directly with sponsors and CROs, showcase its multi-site network, and identify new trial and partnership opportunities for its investigative sites.

“Every conference on this schedule is about the same goal — putting Neutra Life Sciences in front of the sponsors and CROs who can bring new trials into our network,” said Sydney Jim, President and CEO of Neutra Corp. “Adding Partnership with Sites, DPharm, and Fall Clinical – Dermatology gives us more touchpoints with the people who decide where trials go, and we intend to leave each one with new relationships and new opportunities for our sites.”

Industry Conference Presence

As part of its ongoing outreach strategy, Neutra Life Sciences will attend the following industry conferences in 2026:

Partnership with Sites (September 14, 2026) – Partnership with Sites brings together clinical trial site leaders, sponsors, and CROs to explore new collaboration models across the site management landscape. Neutra Life Sciences will attend to connect with sponsors and CROs and highlight its growing multi-site network.

DPharm: Disruptive Innovations to Advance Clinical Trials (September 15–16, 2026) – DPharm convenes pharmaceutical, biotech, and clinical operations leaders to discuss innovative approaches to trial design and execution. Neutra Life Sciences will attend to engage with sponsors and CROs exploring new site partnership models.

Fall Clinical – Dermatology (October 8–11, 2026) – Fall Clinical is a leading dermatology conference bringing together clinicians, researchers, and industry partners. Neutra Life Sciences will attend to strengthen relationships with dermatology sponsors and CROs and showcase its investigative site network in the specialty.

SCRS Global Site Solutions Summit (October 15–18, 2026) – The Society for Clinical Research Sites (SCRS) Global Summit is the premier gathering of clinical research site professionals and industry stakeholders. Neutra Life Sciences will attend to engage with sponsors, CROs, and fellow site operators, showcase its growing multi-site network, and identify new trial and partnership opportunities.

Obesity Week 2026 (November 14–17, 2026) – Obesity Week is the largest international conference dedicated to the science and treatment of obesity, convening leading researchers, clinicians, and industry professionals. Neutra Life Sciences’ attendance underscores its commitment to expanding its therapeutic area footprint and engaging sponsors and CROs active in metabolic and obesity-related clinical research.

Site Update: Women’s Health Care Center of Baytown

Neutra Life Sciences has also successfully started operations at Women’s Health Care Center of Baytown, the clinical research site partnership the Company announced in June 2026. The site is now successfully enrolling patients in two indications — early pregnancy and breast cancer screening — adding to NLS’s growing base of active investigative sites.

For more information about partnering with Neutra Life Sciences, please contact:

info@neutralifesciences.com

www.neutralifesciences.com

About Neutra Corp

Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.

Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.

Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com

About Neutra Life Sciences

Neutra Life Sciences is a clinical research site management organization that is comprised of multiple clinical research sites across various specialties. Their network of Principal Investigators are passionate about advancing medical research and improving healthcare outcomes.

Neutra Life Sciences is dedicated to transforming clinical research through a patient-centric approach. They specialize in optimizing trial operations, enhancing patient experiences, and delivering high-quality data to advance medical innovation.

Their mission is to bridge the gap between cutting-edge clinical trials and the communities that need them most. By fostering strong partnerships with investigators, sponsors, and CROs, we ensure efficient study execution while prioritizing patient safety, comfort, and engagement.

With a team of experienced research professionals, Neutra Life Sciences seamlessly integrates proprietary Standard Operating Procedures (SOPs) with industry best practices to ensure efficiency, compliance, and the highest standards of patient care in every clinical trial we manage. They have an unwavering commitment to excellence, integrity, and innovation drives us to make a meaningful impact in clinical research—one patient at a time.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contacts
Neutra Corp.
Sydney Jim, 307-228-1488
President and CEO
info@neutrainc.com

NOT FOR DISTRIBUTION IN THE UNITED STATES.
FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW

Calgary, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (TSX:AD.UN) (“Alaris” or the “Trust”) is pleased to announce a $100 million bought deal equity offering, a US$95 million investment into a new partner, Nexus Enterprises, LLC (“Nexus”), an amendment to its credit facility, and a 2.6% increase (the “Distribution Increase”) to its quarterly distribution. Unless otherwise stated, all numbers in this press release are presented in Canadian dollars.

The Offering

Alaris has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by CIBC Capital Markets, Acumen Capital Finance Partners Limited and National Bank of Canada Capital Markets, as lead underwriters, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 4,465,000 trust units of the Trust (“Units”) at a price of $22.40 per Unit (the “Offering”) for aggregate gross proceeds of approximately $100 million. The Trust has also granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 669,750 Units issued under the Offering, on the same terms and conditions, exercisable in whole or in part at any time, up to 30 days following closing of the Offering to cover over-allotments and for market stabilization purposes, for additional gross proceeds of up to approximately $15 million.

The Trust intends to use the net proceeds of the Offering (including from the Over-Allotment Option, if applicable) to partially repay outstanding indebtedness under its senior credit facility (the “Senior Credit Facility”), which may be subsequently redrawn and used to fund future investments in new Partners (as defined below) and for general trust purposes.

The Units will be offered by way of short form prospectus which will be filed with the securities regulatory authorities in each of the provinces of Canada, other than the province of Québec and may also be placed privately in the United States in transactions exempt from, among other things, registration under the United States Securities Act of 1933, as amended (the “1933 Act”). Completion of the Offering is subject to customary closing conditions, including receipt of all necessary regulatory and stock exchange approvals, including the approval of the Toronto Stock Exchange. The Offering is expected to close on or about September 28, 2026.

This news release is not an offer of securities of Alaris for sale in the United States. The Units have not been and will not be registered under the 1933 Act, and the Units may not be offered or sold in the United States except pursuant to an applicable exemption from such registration. No public offering of securities is being made in the United States. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Nexus Investment

Alaris is pleased to announce that it has completed a US$95 million investment (the “Nexus Investment”) into Nexus. Nexus provides independent clinical reviews, utilization management services and independent dispute resolution services in the clinical review space.

“Alaris is proud to announce our partnership with the team at Nexus. Nexus has built a wonderful business in the US healthcare dispute resolution industry. The company displays all of the characteristics that have defined Alaris’ investments over our 22 years; free cashflow generation, no debt, low capex and maybe most importantly, an ownership and management team that specifically wanted to stay in the business and build future value. We’re looking forward to facilitating that growth with Ed and his team.” commented Steve King, President and CEO of Alaris.

Alaris’ investment consists of US$75 million of preferred equity (“Preferred Equity”) and US$20 million of common equity. The Preferred Equity investment is broken into US$60 million of non-redeemable preferred equity (subject to standard repurchase rights after three years) and US$15 million of redeemable preferred equity, which is subject to a mandatory cash sweep redemption at par for five years. The Preferred Equity provides Alaris with an initial annualized distribution of US$9.75 million, translating into a pre-tax annualized distribution yield on preferred capital invested of 13%. The distribution will adjust annually based on the percent change in Nexus’ annual gross profit, subject to a collar of +/-8%. The proceeds of the Nexus Investment were used for a minority recapitalization. Alaris expects the Nexus Investment to be accretive to Run Rate Cash Flow on a pro forma basis following the completion of the Offering, including after giving effect to the full exercise of the Over-Allotment Option.

With the closing of the Nexus Investment, Alaris has now deployed approximately $258.2 million in capital year-to-date. The addition of Nexus to Alaris’ suite of Partners reflects Alaris’ disciplined investment strategy targeting strong, profitable private businesses that expand the Trust’s growing and diversified cash flow base through preferred investments, while offering meaningful participation in partner value creation through its common equity investments. 

Distribution Increase

Alongside the Nexus Investment, Alaris is pleased to announce that its board of trustees has approved a 2.6% increase to the Trust’s quarterly distribution. The increase brings the quarterly distribution to $0.39 per Unit and the annual distribution to $1.56 per Unit, with Alaris payout ratio expected to remain within its 65-70% target. Pending formal declaration by the board of trustees, the first increased distribution will be in respect of the Trust’s third quarter distribution payable to unitholders of record on the close of business on September 30, 2026.

Senior Credit Facility Amendments

In connection with the Nexus Investment, Alaris’ subsidiaries completed an amendment to the Senior Credit Facility, which included: (i) increasing the available amount of its Senior Credit Facility to US$500 million from US$450 million; and (ii) a temporary increase in the Funded Debt to Contracted EBITDA (as defined in the Senior Credit Facility) covenant from 3.00:1 to 3.25:1 until the end of the year. The Funded Debt to Contracted EBITDA covenant will revert back to 3.00:1 commencing in the first quarter of 2027.

ABOUT ALARIS

Alaris’ investment and investing activity refers to providing, through the wholly-owned subsidiaries of Alaris (the “Acquisition Entities”), structured equity to private companies (“Partners”) to meet their business and capital objectives, which includes management buyouts, dividend recapitalization, growth and acquisitions. Alaris achieves this by investing its unitholder capital, as well as debt, through the Acquisition Entities, in exchange for distributions, dividends or interest (collectively, “Distributions”) as well as capital appreciation on both preferred and common equity. The principal objective is to generate predictable cash flows for distribution payments to its unitholders while growing net book value through returns from capital appreciation. Distributions, other than common equity Distributions, from the Partners are adjusted annually based on the percentage change of a “top-line” financial performance measure such as gross margin or same store sales and rank in priority to common equity position.

Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws, including any applicable safe harbor provisions. Statements other than statements of historical fact contained in this news release may constitute forward-looking statements, including, without limitation, management’s expectations, intentions and beliefs concerning the growth, results of operations, performance of the Trust and the Partners, the future financial position or results of the Trust, and the business strategy, plans and objectives of or involving the Trust or the Partners. Forward-looking statements may be identified by words such as “believe”, “expects”, “will”, “intends”, “projects”, “anticipates”, “estimates”, “continues” or similar expressions, including the negative thereof. In particular, this news release contains forward-looking statements regarding, among other matters: the completion of the Offering, the exercise of the Over-Allotment Option, the receipt of all necessary regulatory and stock exchange approvals in respect of the Offering, the anticipated use of proceeds of the Offering and the timing of closing of the Offering; the anticipated benefits of the Nexus Investment, the terms of the Nexus Investment and the anticipated distributions to Alaris under the Nexus Investment; the future use of the Senior Credit Facility; the Distribution Increase, Alaris’ anticipated payout ratio and the timing of distributions to unitholders; and the anticipated reversion of the Funded Debt to Contracted EBITDA covenant and the timing thereof. There can be no assurance that the plans, intentions or expectations upon which these forward-looking statements are based will occur.

Forward-looking statements require Alaris to make assumptions and are subject to inherent risks and uncertainties. Assumptions about the performance of the Canadian and U.S. economies over the next 24 months and how that performance may affect Alaris’ business and that of its Partners (including, without limitation, the impact of global health crises and global economic and political factors, including new and ongoing conflicts in Europe and the middle east) are material factors considered by management when establishing expectations for the Trust. Key assumptions include, but are not limited to, assumptions that: the Russia/Ukraine conflict, the Iran conflict, other conflicts in the Middle East and other global economic pressures will not materially impact Alaris, its Partners or the global economy; interest rates and tax rates will not rise materially different from prevailing market expectations over the next twelve months; global health crises thereof will not materially impact the economy or the operations of the Partners over the next twelve months; the businesses of the majority of the Partners will continue to grow; more private companies will require access to alternative sources of capital; the businesses of new Partners and existing Partners will perform in line with Alaris’ expectations and diligence; and that Alaris will have the ability to raise required equity and/or debt financing on acceptable terms. Management has also assumed that the Canadian and U.S. dollar exchange rate will remain within approximately plus or minus 15% of the current rate over the next six months. In determining expectations for economic growth, management considers historical economic data provided by Canadian and U.S. government agencies as well as prevailing economic conditions at the time of such determinations.

Forward-looking statements are subject to risks, uncertainties and assumptions and should not be read as guarantees or assurances of future performance. Actual results of the Trust and the Partners could differ materially from those anticipated as a result of various risk factors, including, but not limited to: global health crises; global economic factors including the Russia/Ukraine conflict, the Iran conflict, other conflicts in the Middle East, inflationary pressures and global supply chain disruptions; tariffs and international trade disputes affecting the Trust or the Partners; failure to complete the Offering on the anticipated terms or at all; risks related to the Partners, including Nexus, and their respective businesses; material changes in the operations of a Partner or the industries in which they operate; changes in the ability of Partners to continue to pay Distributions or restart Distributions (in full or in part); failure to collect deferred Distributions; leverage and restrictive covenants under credit facilities; failure to complete or realize the anticipated benefits of financing arrangements with Partners; and inability to close additional Partner contributions or collect redemption proceeds on anticipated terms. Additional risks that may cause actual results to vary from those indicated are discussed under the headings “Risk Factors” and “Forward-Looking Statements” in Alaris’ Management Discussion and Analysis for the six months ended June 30, 2026 (the “Q2 MD&A”) and Annual Information Form (“AIF”) for the year ended December 31, 2025, which are available under Alaris’ profile at www.sedarplus.ca and on the Trust’s website at www.alarisequitypartners.com.

Readers are cautioned that the assumptions used in the preparation of forward-looking statements, although considered reasonable at the time of preparation, may prove to be inaccurate. Accordingly, undue reliance should not be placed on forward-looking statements. Except as required by applicable law, Alaris undertakes no obligation to update or revise any forward-looking statements.

Non-GAAP and Other Financial Measures

The terms annualized distribution yield on preferred capital invested, Payout Ratio and Run Rate Cash Flow (collectively, the “Non-GAAP and Other Financial Measures”) are financial measures used herein that are not standard measures under IFRS. The Trust’s method of calculating these measures may differ from methods used by other issuers, therefore such may not be comparable to similar measures used by other issuers.

Annualized distribution yield on preferred capital invested is a supplementary financial measure calculated by dividing Partner distribution revenue – preferred, annualized for the period by the weighted average preferred unit capital invested during the period. Management uses this measure to monitor preferred investment distributions over time relative to the current investment base, making it a useful tool for investors to track the cash yield of preferred investments.

Payout ratio is a Non-GAAP financial ratio used by management which represents total cash distributions paid to unitholders during the period, divided by Alaris net distributable cash flow for the same period. This metric is useful to investors as it reflects the proportion of available cash used to pay distributions and indicates the capacity for reinvestment or debt repayment.

Run Rate Cash Flow is a forward-looking supplementary financial measure that outlines the net cash from operating activities, net of distributions paid, that Alaris is expecting to have after the next twelve months. This measure is comparable to Net cash from / (used in) operating activities, less distributions paid, as outlined in Alaris’ consolidated statements of cash flows. Investors find this measure useful because it provides insight into the expected cash available for reinvestment, debt repayment, or other corporate purposes after distributions.

Also see the Q2 MD&A for additional information on the Non-GAAP and Other Financial Measures used by Alaris.

For more information please contact:

Investor Relations
Alaris Equity Partners Income Trust
403-260-1457
ir@alarisequity.com

NOT FOR DISTRIBUTION IN THE UNITED STATES.
FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW

Calgary, Alberta, Sept. 14, 2026 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (TSX:AD.UN) (“Alaris” or the “Trust”) is pleased to announce a $100 million bought deal equity offering, a US$95 million investment into a new partner, Nexus Enterprises, LLC (“Nexus”), an amendment to its credit facility, and a 2.6% increase (the “Distribution Increase”) to its quarterly distribution. Unless otherwise stated, all numbers in this press release are presented in Canadian dollars.

The Offering

Alaris has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by CIBC Capital Markets, Acumen Capital Finance Partners Limited and National Bank of Canada Capital Markets, as lead underwriters, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 4,465,000 trust units of the Trust (“Units”) at a price of $22.40 per Unit (the “Offering”) for aggregate gross proceeds of approximately $100 million. The Trust has also granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 669,750 Units issued under the Offering, on the same terms and conditions, exercisable in whole or in part at any time, up to 30 days following closing of the Offering to cover over-allotments and for market stabilization purposes, for additional gross proceeds of up to approximately $15 million.

The Trust intends to use the net proceeds of the Offering (including from the Over-Allotment Option, if applicable) to partially repay outstanding indebtedness under its senior credit facility (the “Senior Credit Facility”), which may be subsequently redrawn and used to fund future investments in new Partners (as defined below) and for general trust purposes.

The Units will be offered by way of short form prospectus which will be filed with the securities regulatory authorities in each of the provinces of Canada, other than the province of Québec and may also be placed privately in the United States in transactions exempt from, among other things, registration under the United States Securities Act of 1933, as amended (the “1933 Act”). Completion of the Offering is subject to customary closing conditions, including receipt of all necessary regulatory and stock exchange approvals, including the approval of the Toronto Stock Exchange. The Offering is expected to close on or about September 28, 2026.

This news release is not an offer of securities of Alaris for sale in the United States. The Units have not been and will not be registered under the 1933 Act, and the Units may not be offered or sold in the United States except pursuant to an applicable exemption from such registration. No public offering of securities is being made in the United States. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Nexus Investment

Alaris is pleased to announce that it has completed a US$95 million investment (the “Nexus Investment”) into Nexus. Nexus provides independent clinical reviews, utilization management services and independent dispute resolution services in the clinical review space.

“Alaris is proud to announce our partnership with the team at Nexus. Nexus has built a wonderful business in the US healthcare dispute resolution industry. The company displays all of the characteristics that have defined Alaris’ investments over our 22 years; free cashflow generation, no debt, low capex and maybe most importantly, an ownership and management team that specifically wanted to stay in the business and build future value. We’re looking forward to facilitating that growth with Ed and his team.” commented Steve King, President and CEO of Alaris.

Alaris’ investment consists of US$75 million of preferred equity (“Preferred Equity”) and US$20 million of common equity. The Preferred Equity investment is broken into US$60 million of non-redeemable preferred equity (subject to standard repurchase rights after three years) and US$15 million of redeemable preferred equity, which is subject to a mandatory cash sweep redemption at par for five years. The Preferred Equity provides Alaris with an initial annualized distribution of US$9.75 million, translating into a pre-tax annualized distribution yield on preferred capital invested of 13%. The distribution will adjust annually based on the percent change in Nexus’ annual gross profit, subject to a collar of +/-8%. The proceeds of the Nexus Investment were used for a minority recapitalization. Alaris expects the Nexus Investment to be accretive to Run Rate Cash Flow on a pro forma basis following the completion of the Offering, including after giving effect to the full exercise of the Over-Allotment Option.

With the closing of the Nexus Investment, Alaris has now deployed approximately $258.2 million in capital year-to-date. The addition of Nexus to Alaris’ suite of Partners reflects Alaris’ disciplined investment strategy targeting strong, profitable private businesses that expand the Trust’s growing and diversified cash flow base through preferred investments, while offering meaningful participation in partner value creation through its common equity investments. 

Distribution Increase

Alongside the Nexus Investment, Alaris is pleased to announce that its board of trustees has approved a 2.6% increase to the Trust’s quarterly distribution. The increase brings the quarterly distribution to $0.39 per Unit and the annual distribution to $1.56 per Unit, with Alaris payout ratio expected to remain within its 65-70% target. Pending formal declaration by the board of trustees, the first increased distribution will be in respect of the Trust’s third quarter distribution payable to unitholders of record on the close of business on September 30, 2026.

Senior Credit Facility Amendments

In connection with the Nexus Investment, Alaris’ subsidiaries completed an amendment to the Senior Credit Facility, which included: (i) increasing the available amount of its Senior Credit Facility to US$500 million from US$450 million; and (ii) a temporary increase in the Funded Debt to Contracted EBITDA (as defined in the Senior Credit Facility) covenant from 3.00:1 to 3.25:1 until the end of the year. The Funded Debt to Contracted EBITDA covenant will revert back to 3.00:1 commencing in the first quarter of 2027.

ABOUT ALARIS

Alaris’ investment and investing activity refers to providing, through the wholly-owned subsidiaries of Alaris (the “Acquisition Entities”), structured equity to private companies (“Partners”) to meet their business and capital objectives, which includes management buyouts, dividend recapitalization, growth and acquisitions. Alaris achieves this by investing its unitholder capital, as well as debt, through the Acquisition Entities, in exchange for distributions, dividends or interest (collectively, “Distributions”) as well as capital appreciation on both preferred and common equity. The principal objective is to generate predictable cash flows for distribution payments to its unitholders while growing net book value through returns from capital appreciation. Distributions, other than common equity Distributions, from the Partners are adjusted annually based on the percentage change of a “top-line” financial performance measure such as gross margin or same store sales and rank in priority to common equity position.

Forward-Looking Statements

This news release contains forward-looking information and forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws, including any applicable safe harbor provisions. Statements other than statements of historical fact contained in this news release may constitute forward-looking statements, including, without limitation, management’s expectations, intentions and beliefs concerning the growth, results of operations, performance of the Trust and the Partners, the future financial position or results of the Trust, and the business strategy, plans and objectives of or involving the Trust or the Partners. Forward-looking statements may be identified by words such as “believe”, “expects”, “will”, “intends”, “projects”, “anticipates”, “estimates”, “continues” or similar expressions, including the negative thereof. In particular, this news release contains forward-looking statements regarding, among other matters: the completion of the Offering, the exercise of the Over-Allotment Option, the receipt of all necessary regulatory and stock exchange approvals in respect of the Offering, the anticipated use of proceeds of the Offering and the timing of closing of the Offering; the anticipated benefits of the Nexus Investment, the terms of the Nexus Investment and the anticipated distributions to Alaris under the Nexus Investment; the future use of the Senior Credit Facility; the Distribution Increase, Alaris’ anticipated payout ratio and the timing of distributions to unitholders; and the anticipated reversion of the Funded Debt to Contracted EBITDA covenant and the timing thereof. There can be no assurance that the plans, intentions or expectations upon which these forward-looking statements are based will occur.

Forward-looking statements require Alaris to make assumptions and are subject to inherent risks and uncertainties. Assumptions about the performance of the Canadian and U.S. economies over the next 24 months and how that performance may affect Alaris’ business and that of its Partners (including, without limitation, the impact of global health crises and global economic and political factors, including new and ongoing conflicts in Europe and the middle east) are material factors considered by management when establishing expectations for the Trust. Key assumptions include, but are not limited to, assumptions that: the Russia/Ukraine conflict, the Iran conflict, other conflicts in the Middle East and other global economic pressures will not materially impact Alaris, its Partners or the global economy; interest rates and tax rates will not rise materially different from prevailing market expectations over the next twelve months; global health crises thereof will not materially impact the economy or the operations of the Partners over the next twelve months; the businesses of the majority of the Partners will continue to grow; more private companies will require access to alternative sources of capital; the businesses of new Partners and existing Partners will perform in line with Alaris’ expectations and diligence; and that Alaris will have the ability to raise required equity and/or debt financing on acceptable terms. Management has also assumed that the Canadian and U.S. dollar exchange rate will remain within approximately plus or minus 15% of the current rate over the next six months. In determining expectations for economic growth, management considers historical economic data provided by Canadian and U.S. government agencies as well as prevailing economic conditions at the time of such determinations.

Forward-looking statements are subject to risks, uncertainties and assumptions and should not be read as guarantees or assurances of future performance. Actual results of the Trust and the Partners could differ materially from those anticipated as a result of various risk factors, including, but not limited to: global health crises; global economic factors including the Russia/Ukraine conflict, the Iran conflict, other conflicts in the Middle East, inflationary pressures and global supply chain disruptions; tariffs and international trade disputes affecting the Trust or the Partners; failure to complete the Offering on the anticipated terms or at all; risks related to the Partners, including Nexus, and their respective businesses; material changes in the operations of a Partner or the industries in which they operate; changes in the ability of Partners to continue to pay Distributions or restart Distributions (in full or in part); failure to collect deferred Distributions; leverage and restrictive covenants under credit facilities; failure to complete or realize the anticipated benefits of financing arrangements with Partners; and inability to close additional Partner contributions or collect redemption proceeds on anticipated terms. Additional risks that may cause actual results to vary from those indicated are discussed under the headings “Risk Factors” and “Forward-Looking Statements” in Alaris’ Management Discussion and Analysis for the six months ended June 30, 2026 (the “Q2 MD&A”) and Annual Information Form (“AIF”) for the year ended December 31, 2025, which are available under Alaris’ profile at www.sedarplus.ca and on the Trust’s website at www.alarisequitypartners.com.

Readers are cautioned that the assumptions used in the preparation of forward-looking statements, although considered reasonable at the time of preparation, may prove to be inaccurate. Accordingly, undue reliance should not be placed on forward-looking statements. Except as required by applicable law, Alaris undertakes no obligation to update or revise any forward-looking statements.

Non-GAAP and Other Financial Measures

The terms annualized distribution yield on preferred capital invested, Payout Ratio and Run Rate Cash Flow (collectively, the “Non-GAAP and Other Financial Measures”) are financial measures used herein that are not standard measures under IFRS. The Trust’s method of calculating these measures may differ from methods used by other issuers, therefore such may not be comparable to similar measures used by other issuers.

Annualized distribution yield on preferred capital invested is a supplementary financial measure calculated by dividing Partner distribution revenue – preferred, annualized for the period by the weighted average preferred unit capital invested during the period. Management uses this measure to monitor preferred investment distributions over time relative to the current investment base, making it a useful tool for investors to track the cash yield of preferred investments.

Payout ratio is a Non-GAAP financial ratio used by management which represents total cash distributions paid to unitholders during the period, divided by Alaris net distributable cash flow for the same period. This metric is useful to investors as it reflects the proportion of available cash used to pay distributions and indicates the capacity for reinvestment or debt repayment.

Run Rate Cash Flow is a forward-looking supplementary financial measure that outlines the net cash from operating activities, net of distributions paid, that Alaris is expecting to have after the next twelve months. This measure is comparable to Net cash from / (used in) operating activities, less distributions paid, as outlined in Alaris’ consolidated statements of cash flows. Investors find this measure useful because it provides insight into the expected cash available for reinvestment, debt repayment, or other corporate purposes after distributions.

Also see the Q2 MD&A for additional information on the Non-GAAP and Other Financial Measures used by Alaris.

For more information please contact:

Investor Relations
Alaris Equity Partners Income Trust
403-260-1457
ir@alarisequity.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.